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Summary
The caveolin gene family has three members in vertebrates: caveolin-1, caveolin-2, and caveolin-3.
So far, most caveolin-related research has been conducted in mammals, but the proteins have
also been found in other animals, including Xenopus laevis, Fugu rubripes, and Caenorhabditis elegans.
Caveolins can serve as protein markers of caveolae (‘little caves’), invaginations in the plasma
membrane 50-100 nanometers in diameter. Caveolins are found predominantly at the plasma
membrane but also in the Golgi, the endoplasmic reticulum, in vesicles, and at cytosolic locations.
They are expressed ubiquitously in mammals, but their expression levels vary considerably
between tissues. The highest levels of caveolin-1 (also called caveolin, Cav-1 and VIP21) are found
in terminally-differentiated cell types, such as adipocytes, endothelia, smooth muscle cells, and
type I pneumocytes. Caveolin-2 (Cav-2) is colocalized and coexpressed with Cav-1 and requires
Cav-1 for proper membrane targeting; the Cav-2 gene also maps to the same chromosomal
region as Cav-1 (7q31.1 in humans). Caveolin-3 (Cav-3) has greater protein-sequence similarity to
Cav-1 than to Cav-2, but it is expressed mainly in muscle cells, including smooth, skeletal, and
cardiac myocytes. Caveolins participate in many important cellular processes, including vesicular
transport, cholesterol homeostasis, signal transduction, and tumor suppression. 
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Gene organization and evolutionary history 
Research into caveolae began with their morphological identi-
fication in 1953. By transmission electron microscopy, they
appear as structures resembling ‘little caves’, which are vesicu-
lar invaginations of the plasma membrane of 50-100 nano-
meters (nm) in size [1]. Caveolin-1 (also known as caveolin,
Cav-1 or VIP21) was the first member of the caveolin family to
be identified, and it was shown to be a structural component
of caveolae and of transport vesicles derived from the trans-
Golgi network [2,3]. It was isolated as one of several proteins
that became phosphorylated on tyrosine residues in chicken
embryo fibroblasts transformed with the v-Src oncogene [4].
Monoclonal antibodies directed against Cav-1 decorated the
cytoplasmic protein coat of caveolae, making Cav-1 the first
true protein marker of caveolae [2]. Subsequent cloning of the
Cav-1 cDNA revealed that it was identical to another protein,
VIP21, which had been cloned almost simultaneously [3,5].
Interestingly, VIP21 was isolated as an integral membrane
protein component of transport vesicles derived from the
trans-Golgi network in Madin-Darby canine kidney (MDCK)
cells, suggesting that Cav-1/VIP21 may have a role in molecu-
lar trafficking as well as oncogenesis.
Caveolin-2 (Cav-2) and caveolin-3 (Cav-3) were identified in
1996 using different experimental methods. Cav-2 was dis-
covered by the microsequencing of a 20 kDa protein that co-
purified with adipocyte-derived caveolar membranes [6].
Further characterization revealed that Cav-2 colocalizes with
Cav-1 in caveolae, forms hetero-oligomers with Cav-1, is
co-expressed in many of the same cells and tissues, and
requires Cav-1 for proper membrane localization [7,8].
Cav-3 (also known as M-caveolin) was identified throughdatabase searches and traditional cDNA library screening in
an attempt to find Cav-1 homologs [9,10]. 
Caveolin sequences have been obtained from a range of ver-
tebrates, including human, cow, mouse, Xenopus, and Fugu
rubripes. A caveolin gene family has also been found in
Caenorhabditis elegans [11,12]. The three mammalian genes
encoding members of the caveolin family are similar in
sequence (Table 1). A phylogenetic tree of all known cave-
olins shows that the C. elegans Cav-1 sequence is only dis-
tantly related to all the others (Figure 1). Interestingly, Cav-1
and Cav-2 are in very close proximity (about 19 kilobases
(kb) apart) on human chromosome 7q31.1, while Cav-3 is
located on a different chromosome (3p25) [13,14]. Although
the evolutionary history of the caveolin genes has not been
clearly defined, there are clues within their sequences and
genomic organization to suggest possible mechanisms for
their origin. For instance, although C. elegans Cav-1 has two
exons, the region that is homologous to mammalian cave-
olins is encoded by only a single exon, suggesting that mam-
malian caveolins are derived from this particular exon [11].
Also, two observations derived from the human genomic
sequence suggest that some family members may have
arisen through gene duplication events: firstly, the exon-
intron boundaries in the last exons of Cav-1, Cav-2, and
Cav-3 are in analogous positions; and secondly, exon 2 of
Cav-2 is divided into two parts (2a and 2b) by an intron,
whereas the two homologous portions in the Cav-1  and
Cav-3 sequences are fused together to form the final exon
[13,14]. This second point may suggest that Cav-2 served as
the genomic precursor of Cav-1 and Cav-3.
Characteristic structural features
Currently, the structural features of this family of proteins
are poorly defined, but information gleaned from the protein
sequence has enabled some predictions of structure and
motifs within the proteins. For instance, all three caveolins
have an invariant ‘FEDVIAEP’ stretch (in the single-letter
amino-acid code) within their hydrophilic amino-terminal
domains that has come to be termed the ‘caveolin signature
motif’ [6,9]. The functional importance of this sequence or
motif has yet to be determined, however. 
Two Cav-1 isoforms ( and ) have been identified; the 
isoform arises from an internal translational start site that
gives a shorter amino terminus than that of the  form and is
truncated by 31 residues [15]. The predicted domains span
almost the same number of residues in all three proteins: the
amino-terminal domain comprises the first 101 residues in
Cav-1 and the first 70-86 residues in Cav-1, Cav-2, and
Cav-3, with the putative transmembrane domain occupying
33 amino acids and the carboxy-terminal domain containing
43-44 amino acids (Figure 2). 
Using a variety of experimental methods, it has been deter-
mined that the major sub-cellular location of Cav-1 is at the
plasma membrane. From the primary sequence (hydrophilic-
ity plots) and mutational analysis, Cav-1 is predicted to have a
membrane-spanning hairpin-like structure, with both amino
and carboxyl termini directed towards the cytoplasm
(Figure 2). This atypical membrane-spanning model is sup-
ported by findings that antibodies directed against the Cav-1
amino or carboxyl terminus require cells to be permeabilized
in order to bind Cav-1, that cell-surface biotinylation does not
label Cav-1, and that there are known palmitoylation and
tyrosine phosphorylation sites within both the amino- and
the carboxy-terminal domains of the protein [16-19]; palmi-
toylation and tyrosine phosphorylation are both cytoplasmi-
cally generated post-translational modifications. 
Generally speaking, caveolins are small proteins (18-24 kDa).
Structurally, however, perhaps one of the most interesting
and significant findings about Cav-1 is that it forms an
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Table 1
Genomic organization of the human caveolin genes and properties of their protein products
Human Chromosomal Exon Exon  Intron Intron  Residues  Length  of  Percentage  Percentage  Expression 
gene location size size  encoded  protein  similarity  similarity  patterns
(bp) (kb) by exon (amino  (identity) to (identity) to 
acids) human Cav-1 human Cav-2
Cav-1 7q31.1 1 30 1 1.47 1-10 178  59 (40) Ubiquitous; highest levels in 
2 165 2 31.8 11-65 - adipocytes, endothelia, 
3 342 66-178 smooth muscle cells, and 
Type I pneumocytes
Cav-2 7q31.1 1 150 1 0.33 1-50 162 58 (38) - Co-expressed with Cav-1
2a 188 2 5.76 51-112
2b 151 113-162
Cav-3 3p25 1 114 1 ? 1-38 151 85 (65) 60 (39) Muscle-specific; primarily in 
2 342 39-151 skeletal and cardiac myocytes
Abbreviations: bp, base pairs; kb, kilobases; ?, unknown. Modified from Razani et al. [42].oligomeric complex comprised of approximately 14-16
monomers, as discovered through velocity gradient ultracen-
trifugation. In this assay system, Cav-1 was found to migrate
as 200-400 kDa complexes [16,20]. Experiments with Cav-1
deletion mutants mapped the oligomerization domain to
residues 61-101 [16] (Figure 2). Interestingly, Cav-3 also
forms large oligomeric complexes of approximately 350-400
kDa in vivo, whereas Cav-2 requires Cav-1 to participate in
the formation of these high-molecular-mass complexes [7-9]. 
Localization and function
Caveolae are considered by many to be a subset of lipid
rafts, which are highly-ordered microdomains residing
within the plasma membrane that are enriched in certain
lipids [21-23]; this may not be completely accurate,
however, as some proteins are known to localize selectively
to either lipid rafts or caveolae but not both [24]. Caveolae-
enriched membrane fractions can be purified efficiently on
the basis of their buoyancy and resistance to solubilization
by mild non-ionic detergents at 4°C [25-30], but other types
of membrane microdomains may also be enriched by this
kind of purification.
Cav-1 localizes to plasma-membrane caveolae and also to the
Golgi apparatus and trans-Golgi-derived transport vesicles
[3,5,31]. Cav-1 may have a soluble cytoplasmic form, as well
as a secreted form, depending on the cell type [32], and the
first 31 amino acids may be important in selectively targeting
isoforms of Cav-1 to different cellular compartments [33].
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Figure 1 
A phylogenetic tree depicting the evolutionary relationships of all known caveolin protein sequences. Note that C. elegans Cav-2 was not included in this
analysis because of its low similarity to the mammalian caveolins. GenBank-derived protein sequences were entered into the ClustalW program to
generate a phylogenetic tree using the neighbor-joining method. Numbers indicate horizontal branch lengths, which correspond to the estimated
evolutionary distances between the protein sequences. 
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 Xenopus Cav-2Cav-1 is expressed ubiquitously, although at different levels
in different tissues, with the highest levels in adipocytes,
endothelial cells, fibroblasts, smooth-muscle cells, and a
variety of epithelial cells. Cav-2 is tightly co-expressed with
Cav-1, whereas Cav-3 is expressed predominantly in striated
muscle cells [34]. Interestingly, Cav-1 is required for the
proper membrane localization of Cav-2.
Mice deficient in Cav-1,  Cav-2, or Cav-3  are viable and
fertile, but each has abnormal cellular and tissue-specific
phenotypes peculiar to the specific ablated gene [35-43]. A
mutant form found in up to 16% of human breast cancers,
Cav-1 (P132L), does not localize properly to the plasma mem-
brane and behaves in a dominant-negative manner, causing
the mislocalization and intracellular retention of wild-type Cav-
1 [44,45]. An analogous P-to-L mutation in Cav-3 (P104L) has
been detected in patients with autosomal dominant limb-girdle
muscular dystrophy type-1C, and this mutation also behaves
in a dominant-negative fashion [46-49]. Wild-type Cav-3
localizes to caveolae and the plasma membrane and also
associates with the T tubules that form from invaginations of
the muscle membrane [50,51]. 
Caveolin-related research has shown that caveolae function
in vesicle trafficking [52], cholesterol homeostasis, signal
transduction and tumor suppression. Endothelial caveolae
may be involved in transcytosis; they have the molecular
components used by other transport vesicles during vesicle
formation, docking, and fusion [53], and the motor protein
dynamin, which is important for vesicle fission, also localizes
to caveolae [54,55]. Regarding endocytosis, it appears that
certain ligands and extracellular molecules, such as cholera
and tetanus toxins, are transported across the plasma mem-
brane through caveolae, rather than via clathrin-dependent
mechanisms [56,57]. Pathogens appear to have evolved
mechanisms to gain entry into eukaryotic cells through
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Figure 2 
Primary structure and topology of Cav-1. (a) The predicted membrane topology of Cav-1. Two caveolin-1 monomers are shown forming a dimer for
simplicity, but about 14-16 monomers normally self-associate to form a single caveolin homo-oligomer (the caveolar assembly unit, akin to the clathrin
triskelion). Note that both the amino- and carboxy-terminal domains are oriented towards the cytosolic face of the plasma membrane, with a hairpin
loop structure inserted within the membrane bilayer. Modified from Razani et al. [42]. (b) The domains present in Cav-1. Note that the amino-terminal
membrane-attachment domain is also called the caveolin scaffolding domain (CSD).
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(b)caveolae, including simian virus 40 and certain strains of
Escherichia coli [58]. 
Caveolae are enriched with cholesterol and Cav-1 is one of
the few proteins that binds cholesterol tightly and specifi-
cally [59,60]; free cholesterol is required for the proper for-
mation of caveolae [61-63] and regulates the Cav-1 promoter
[64]. Intracellular cholesterol balance may be affected by
caveolins [65], as a dominant-negative Cav-1 mutant causes
intracellular retention of free cholesterol as well as a
decrease in cholesterol synthesis and its efflux from the cell
[66]. Also, caveolae have been linked to the process of
reverse cholesterol transport, during which excess free cho-
lesterol is released into the blood plasma via uptake by high-
density lipoprotein (HDL) particles [67-71], and caveolae
appear to be involved in the uptake of cholesterol esters
from the plasma.
Caveolae appear to serve as signaling platforms by compart-
mentalizing and concentrating signaling molecules (this is
referred to as the ‘caveolae signaling hypothesis’) [27].
Various classes of signaling molecules, including G-protein
subunits, receptor and non-receptor tyrosine kinases,
endothelial nitric oxide synthase (eNOS), and small GTPases
[27,42], bind Cav-1 through its ‘caveolin-scaffolding domain’
(CSD) (Figure 2). Cav-1 also appears to inhibit the down-
stream activation and signaling of many proteins, including
c-Src, H-Ras, mitogen-activated protein (MAP) kinases, and
eNOS [72-78]. The evidence that Cav-2 is a signaling modu-
lator is less clear, partly perhaps because its CSD sequence is
divergent from that of Cav-1. The Cav-3 CSD is very similar
to the Cav-1 CSD, however, and Cav-3-generated caveolae
have been shown to compartmentalize and modulate a
number of signaling proteins, including eNOS, -adrenergic
receptors, protein kinase C isoforms, G proteins, Src-family
kinases, and multiple components of the dystrophin-glyco-
protein complex [34,76-79].
Several lines of evidence have implicated Cav-1 in tumor
suppression [18,19,80-84], and there is also accumulating
evidence that Cav-1 has an anti-proliferative function. Fur-
thermore, the Cav-1 and  Cav-2  genes are close to the
microsatellite marker D7S522 on human chromosome
7q31.1 [13,14], a region that is commonly deleted and impli-
cated in the pathogenesis of many human epithelial-based
cancers, including breast, colorectal, prostate, ovarian, and
renal-cell carcinomas. Recent results [85-90] strongly argue
that Cav-1 functions either as a negative regulator of cell pro-
liferation or as a tumor suppressor, in both cultured cells
and whole animals. 
Frontiers
The ubiquitous nature and diverse tissue expression of cave-
olin family members in mammals suggest that caveolins are
indeed important for normal cellular and tissue physiology
in highly evolved organisms. The discovery of a caveolin
gene family in the invertebrate C. elegans [11] raises the
questions of when caveolins joined the cellular repertoire
and whether they are present in more primitive animals,
plants or fungi. Another equally important area of research
is deciphering the structure of caveolins, as such knowledge
would greatly contribute to our understanding of how cave-
olins function. Recently, gene knockout and transgenic tech-
nology has facilitated the study of caveolins in mice, from a
whole-organism point of view, allowing the generation of
caveolin-deficient or caveolin-overexpressing transgenic
mice. The molecular-genetic analysis of these caveolin-defi-
cient mouse models, and cell lines derived from these
animals, will greatly facilitate the progress of caveolae-
related research into the next decade. 
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